Novartis AG - 28 Year Stock Price History | NVS

Historical daily share price chart and data for Novartis AG since 1996 adjusted for splits and dividends. The latest closing stock price for Novartis AG as of April 22, 2024 is 95.12.
  • The all-time high Novartis AG stock closing price was 104.52 on January 22, 2024.
  • The Novartis AG 52-week high stock price is 108.78, which is 14.4% above the current share price.
  • The Novartis AG 52-week low stock price is 92.19, which is 3.1% below the current share price.
  • The average Novartis AG stock price for the last 52 weeks is 99.95.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novartis AG Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 98.6608 97.3214 104.5193 92.5700 95.1200 -2.23%
2023 92.2155 85.1299 101.3010 76.8948 97.2925 16.16%
2022 78.2204 77.8900 86.5516 68.8813 83.7543 8.02%
2021 77.4454 80.5651 84.3343 70.6479 77.5354 -3.82%
2020 74.1311 78.1740 81.5167 60.3321 80.6164 3.41%
2019 70.5993 60.7647 78.5198 60.7647 77.9599 25.68%
2018 59.4776 59.0848 66.1645 52.3649 62.0297 5.88%
2017 55.8987 49.0561 60.4594 47.1701 58.5824 19.40%
2016 51.4035 55.6494 56.2498 45.5266 49.0628 -12.13%
2015 62.8707 58.2286 68.8689 54.4877 55.8376 -4.53%
2014 55.3316 48.0810 61.0059 47.7634 58.4874 19.13%
2013 44.4117 37.5627 49.1010 37.4862 49.0949 31.80%
2012 33.6326 32.7732 37.6392 30.2950 37.2508 15.67%
2011 32.1284 31.9978 36.3446 29.0948 32.2043 1.14%
2010 28.5023 27.4130 32.2841 23.6473 31.8412 12.27%
2009 23.1317 24.7189 29.2628 17.6952 28.3614 14.23%
2008 25.6303 26.4529 30.4671 21.8798 24.8287 -5.69%
2007 26.8308 27.6575 28.6149 25.0132 26.3269 -3.65%
2006 26.7583 25.0158 29.1321 24.6891 27.3245 11.29%
2005 23.1684 23.1168 25.5913 21.4040 24.5527 5.64%
2004 21.0901 20.7367 23.2777 18.9919 23.2409 12.10%
2003 17.5939 16.4430 20.7322 14.4486 20.7322 27.36%
2002 17.2502 15.6557 19.4258 15.0039 16.2790 1.96%
2001 16.6925 19.3337 19.4157 14.4265 15.9663 -17.31%
2000 15.5580 15.1100 19.3079 12.4369 19.3079 26.91%
1999 16.2807 21.2659 21.4713 14.5118 15.2139 -24.44%
1998 17.5263 16.7812 20.7008 14.8450 20.1358 21.46%
1997 14.3182 10.9213 17.2152 10.4434 16.5775 50.81%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $194.425B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $694.884B 115.72
Novo Nordisk (NVO) Denmark $562.108B 46.31
Johnson & Johnson (JNJ) United States $359.347B 14.26
Merck (MRK) United States $321.543B 84.63
AbbVie (ABBV) United States $297.274B 15.11
AstraZeneca (AZN) United Kingdom $217.434B 19.27
Pfizer (PFE) United States $148.698B 14.35
Sanofi (SNY) $119.271B 10.74
Innoviva (INVA) United States $0.944B 6.67